Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Appili Therapeutics Inc Class A ( (TSE:APLI) ) has issued an update.
Appili Therapeutics announced that its CEO, Don Cilla, will join Aditxt’s CEO for a discussion on emerging infectious diseases and strategic partnerships. The event will highlight Appili’s operational achievements, including $117 million in new federal funding applications, and the ongoing going-private transaction with Aditxt. The discussion will also emphasize Appili’s success in securing non-dilutive funding and its plans to accelerate the development of treatments for infectious diseases.
More about Appili Therapeutics Inc Class A
Appili Therapeutics is a biopharmaceutical company focused on developing drugs for infectious diseases and medical countermeasures. The company aims to address urgent infections with unmet needs through a diverse pipeline of novel therapies, including an FDA-approved suspension of metronidazole, a vaccine candidate against biological threats, and a topical antiparasitic treatment.
YTD Price Performance: -16.67%
Average Trading Volume: 85,895
Technical Sentiment Signal: Buy
Current Market Cap: $2.97M
For detailed information about APLI stock, go to TipRanks’ Stock Analysis page.